In the case of PAAD, we analyzed 308 PAAD patients with a frequency of MVP gene alterations up to 1.62%, containing a “mutation” rate of 0.65% and an “amplification” rate of 0.97% (Figure 7B). The gene discussed is MVP; the disease is pancreatic adenocarcinoma.